MedTrace Logo

Zelquistinel in the Treatment of Major Depressive Disorder

NCT03586427 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2026-04-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

AGN-241751

AGN-241751 administered orally as a single tablet

DRUG

Placebo

Placebo administered orally as a single tablet

Sponsors & Collaborators

  • Syndeio Biosciences, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2019-07-22
Completion
2019-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03586427 on ClinicalTrials.gov